Moscow City Hospital No 29

Background/Objectives: This study aims to fill certain knowledge gaps by assessing the clinical effectiveness of PDT in a large group of women with HPV-related cervical lesions and examining how different patient factors affect treatment results. Methods: A total of 811 women aged from 19 to 76 were retrospectively analyzed who were treated by PDT of HPV infection with atypical squamous cells and HPV-related cervical lesions. PDT was performed using chlorin e6-based systemic photosensitizers. Irradiation was carried out at 662 nm. The endocervical dose was 334 J/cm2, and the ectocervical dose was 291 J/cm2. Results: Overall HPV clearance was 91.1%, lesion remission was 95.3%, and complete response was 88.3%, with the highest complete response observed in the HSIL group compared with HPV-positive ASCs. Multivariable models showed that multiple HPV infection (especially >3 genotypes) and pregnancy history were associated with lower odds of complete response, while younger age (18-25 years) and TZ2 were associated with higher odds of complete response. Conclusions: PDT using chlorin e6-based photosensitizers demonstrated high clinical and virological effectiveness across HPV-related cervical abnormalities, including HSIL, supporting its role as an organ-preserving treatment option. Multiple HPV genotypes and pregnancy history may identify patients at increased risk of partial response and warrant closer follow-up or tailored treatment strategies.

Background. Adjuvant targeted therapy (ATT) with a combination of dabrafenib and trametinib after radical surgical treatment in patients with stage III skin melanoma (SM) with a BRAF V600 mutation reduces the risk of disease recurrence. The effectiveness of this approach has been demonstrated in randomized clinical trials, and also confirmed in several large non-Russian real-world (RW) studies. Aim. To evaluate, in RW settings, the effectiveness of ATT with a combination of dabrafenib and trametinib after definitive surgical treatment in patients with BRAF V600-positive SM in Russia. Materials and methods. The RATIONALE study is a prospective, non-interventional, multicenter RW study. The follow-up duration for the study was 1 year. Patients with SM older than 18 years who had previously started dabrafenib and trametinib therapy no more than 8 weeks prior to Visit 1 were included in the study. The paper presents results from the analysis of Cohort 1 only (patients who received dabrafenib and trametinib in the adjuvant setting). Results. The cohort included 214 patients with BRAF V600-mutated SM of stages IIIA–D and IV resectable. At the time of therapy initiation, the majority of patients were stage IIIc (54.7%) or IIIb (22.0%). The most common mutation – BRAF V600E – occurred in 66.3% of cases, while the second most common variant – BRAF V600 not otherwise specified – was detected in 31.3%. One-year overall survival for all included patients was 94%, one-year relapse-free survival was 84%, and one-year distant metastasis-free survival was 86%. No previously listed adverse events were reported. Adverse events led to therapy discontinuation in only 11.7% of cases. ATT did not reduce patients' quality of life. In the subgroup analysis, the effectiveness of the combination of dabrafenib and trametinib after removal of distant metastases (equivalent to stage IV resectable) was found, in particular, the one-year relapse-free survival rate was 83%, and the one-year overall survival rate was 100%, which is comparable to these indicators for stage IIIB-D (72–86 and 78–100%, respectively). Conclusion. The effectiveness and favorable safety profile of the combination of dabrafenib and trametinib in ATT after radical surgical treatment was confirmed in a population of Russian patients with SM in the RW settings.

Abstract Background and Aims Transplant renal artery stenosis (TRAS) is the most common vascular complication after kidney transplantation (KTx). Duplex ultrasonography (DUS) is a primary noninvasive modality for diagnosing of TRAS. The prompt surgical repair of TRAS leads to significant regression of kidney allograft (KA) dysfunction and stabilization of blood pressure indicators. The objective of this study is to investigate the impact of resistive index (RI) after successful percutaneous transluminal stenting (PTS) on the survival of KA and recipients. Method 62 patients after successful PTS were included into a single-center retrospective study from June 2018 to June 2024. The diagnosis of TRAS was detected by DUS. 58 patients underwent control DUS in 7–10 days after PTS, 2 patients were lost for follow-up. The peak systolic velocity (Vmax) and the minimal diastolic velocity (Vmin) were determined in the segmental arteries with a convex transducer (Vivid E90, GE, USA). The RI was calculated as [1−(Vmin ÷ Vmax)]. Results of three measurements at three places in the transplant (lower/middle/upper parts) were averaged measured RI. The combined end point was terminal transplant failure requiring the re-institution of dialysis or death from any cause. Statistical analysis was performed using the STATISTICA 13 and Online ROC Curve Calculator (Johns Hopkins University School of Medicine). Results A total of 56 recipients were included. In a ROC analysis, we defined a cut-off value of the RI of 0.79 (True Positive Fraction 0.82, False Positive Fraction 0.12, Fitted ROC Area 0.9). Therefore, the observation group was divided into two subgroups: (1 sgr) 45 patients with an RI < 0.79 and (2 sgr) 11 patients with an RI ≥ 0.79. The results of comparative analyses of demographic, clinical and laboratory data are presented in Table. The study subgroups did not significantly differ in age, gender, donor's age, Diabetes Mellitus, duration of replacement therapy, mean Blood Pressure, Pulse Pressure and Pcr at the time of TRAS diagnosis. Patients with an RI of 0.79 or higher were more likely to suffer from coronary heart disease and chronic occlusive disease of the lower limb arteries. The significant differences in Pcr were detected in subgroups within 7–10 days and a month after PTS, the patients with an RI of 0.79 or higher demonstrated higher Pcr. 3 (27.3 %) patients with an RI of 0.79 or higher have lost graft function (1 patient – KTx, 2 patients – hemodialysis) and 2 patients (18.2 %) died (1 – from sepsis, 1 – from progressive heart failure). All patients with an RI of less than 0.79 are alive with preserved KA function. The results of cumulative survival are presented in the Fig. 1. Conclusion RI of 0.79 or higher after successful PTS in patients with TRAS, as compared with a lower RI, is associated with progressive renal dysfunction and adverse outcomes.

.

The present article contains the newest ant the most actual version of clinical recommendations “Gestational diabetes mellitus” of the Russian Ministry of Health. This document has been confirmed for the period from 2024 until 2026 year. Gestational diabetes mellitus is widely known as onset of hyperglycaemia during pregnancy that does not responds to criteria of manifesting diabetes mellitus (DM). The time of next revision is 2026 year or earlier if new evidentiary material appear. The present version of clinical recommendation has been created due to collaboration between Russian Association of Endocrinologists and Russian Society of Obstetricians and Gynecologists. The document is finally approved by scientific and practical Council of the Russian Ministry of Health.

In modern surgery of complicated cataracts, an important factor is the preservation of visual functions with minimal costs. The surgeon’s experience and modern technology, which makes it possible to identify hidden symptoms of certain pathologies at the diagnostic stage, allows for a favorable completion of surgery with minimal intraoperative complications. This article shows the approach and observations of patients at risk of increasing eye pressure in the postoperative period due to the anatomical structures of the eye (in these cases, patients with open-angle glaucoma) to antihypertensive drugs. 131 patients (134 eyes) with various signs of pseudoexfoliation syndrome participated in the observation. Before planned surgery for complicated cataracts, all patients underwent ophthalmological diagnostics, medical history, and laboratory tests according to generally accepted methods. All operations were performed by the same surgeon. Cataract surgery was performed according to the standard technique (Phaco + intraocular lens) through a 2.2 mm incision, two 1.2 mm paracentesis, but for some patients other components of surgical interventions were added. In the observation groups, for better fixation and a lower percentage of complications in long-term follow-up periods, RPR, T-19, Myol were implanted in 27.7%. A large percentage of 34% were implanted with the HO Acrylic IOL model lens, which requires a 2.2 mm corneal incision. In observation groups 2 and 3, 32.5 and 31.8% preferred lenses to the Acrysoft IQ model. And in 32.5% and 13.6%, respectively, the AFY model. The choice of the method of surgical intervention, as well as the model of intraocular lenses, made it possible to predict the long-term postoperative period with less toxicity for the patient’s condition. No intraoperative complications were observed; the administration of antihypertensive drops, both in combination and in monotherapy in the early stages of the postoperative period, allowed maintaining eye pressure within normal limits in all observation groups.

Introduction. Currently, the incidence of kidney diseases among adult population is growing. It is expected to become the fifth leading cause of death by 2040. Showing no symptoms at early stages, chronic kidney disease (CKD) is closely related to diabetes mellitus, hypertension, obesity and kidney dysfunction in older age, which requires long-term and expensive treatment. Organization structure and the strategy of medical care provided by Moscow nephrology service is aimed at implementing measures for risk prevention and active early detection of kidney disease, as well as informing general population and medical community about existing diagnostic methods, modern treatment options and schemes. The purpose of the study was to identify trends in CKD prevalence and incidence among able-bodied population in the context of Moscow nephrology service improvement. Materials and Methods. An analysis of disease prevalence and incidence among able-bodied population based on official statistics data of the Russian Research Institute of Health (RIH) of the Ministry of Health of the Russian Federation and the Centre of Medical Statistics of Moscow Healthcare Department was carried out; indicators of time series and average growth/decrease rates were calculated. In order to identify a long-term trend, least squares method was used. Incidence rates were expressed per 100,000 able-bodied population. Results. In 2022, the overall disease prevalence in Moscow was lower than for the country as a whole (31.3 and 74.2 cases per 100,000 population, respectively), while incidence of the able-bodied population in Moscow was lower than countrywide (2.9 and 11.5 cases per 100,000 population, respectively). The long-term dynamics of CRD prevalence and incidence was generally characterized by an upward trend. Thus, the average annual incidence in Moscow was 9.8% and 6.1%, while in the Russian Federation 7.2% and 5.4%, respectively. On average, 91.3% of able-bodied patients with CKD in Moscow are under follow-up monitoring for a year. The number of dispensary patients with CKD increased by 2.5 times in 2022 in comparison to 2013, from 11.7 to 29.5 per 100,000 population, respectively. Since 2016, patients with newly diagnosed CKD have been provided with 100% coverage of follow-up monitoring.